DVA DaVita
FY2025 10-K
DaVita (DVA) filed its fiscal year 2025 10-K annual report with the SEC on Feb 11, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Providing kidney care services with significant revenues from commercial insurance and government programs like Medicare, Medicaid, and Veterans Affairs
- • New emphasis: Expansion in integrated kidney care offerings including home-based dialysis, U.S. integrated kidney care business, and ancillary services
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in provided MD&A section
- • Forward-looking risks include reimbursement rate declines, patient mix shifts, and increased competition pressures
Risk Factors
- • Legal risk: accrual for potential third-party judgment costs of $25 million for unspecified legal matters
- • Macroeconomic exposure: $10.16 billion long-term debt principal maturity with $5.29 billion due after 2030
Financial SummaryXBRL
Revenue
$13.6B
Net Income
$747M
Operating Margin
15.0%
Net Margin
5.5%
ROE
-114.7%
Total Assets
$17.5B
EPS (Diluted)
$9.84
Operating Cash Flow
$1.9B
Source: XBRL data from DaVita FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on DaVita
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.